35,200 Shares in Ascendis Pharma A/S $ASND Acquired by Atika Capital Management LLC

Key Points

• Atika Capital Management LLC has acquired a new stake in Ascendis Pharma A/S, investing approximately $5.49 million for 35,200 shares, representing about 0.06% ownership by the end of the last quarter.
• Several institutional investors significantly increased their stakes in Ascendis Pharma A/S, with T. Rowe Price Investment Management growing its holdings by 54.4% during the fourth quarter.
• Analysts have raised their price targets on Ascendis Pharma A/S, with UBS Group setting a new target at $307.00, reflecting strong confidence in the stock's performance.

Atika Capital Management LLC bought a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 35,200 shares of the biotechnology company's stock, valued at approximately $5,486,000. Atika Capital Management LLC owned approximately 0.06% of Ascendis Pharma A/S at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. HighTower Advisors LLC grew its stake in shares of Ascendis Pharma A/S by 413.1% in the 1st quarter. HighTower Advisors LLC now owns 18,032 shares of the biotechnology company's stock worth $2,810,000 after acquiring an additional 14,518 shares in the last quarter. Pursue Wealth Partners LLC purchased a new position in shares of Ascendis Pharma A/S in the 1st quarter worth about $226,000. Geode Capital Management LLC boosted its holdings in shares of Ascendis Pharma A/S by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 57,077 shares of the biotechnology company's stock worth $7,858,000 after buying an additional 629 shares during the last quarter. Sigma Planning Corp purchased a new position in shares of Ascendis Pharma A/S in the 1st quarter worth about $236,000. Finally, Diversify Advisory Services LLC purchased a new position in shares of Ascendis Pharma A/S in the 1st quarter worth about $332,000.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND traded up $4.08 during trading on Tuesday, hitting $194.45. 67,167 shares of the company's stock traded hands, compared to its average volume of 491,443. The stock has a market capitalization of $11.90 billion, a price-to-earnings ratio of -37.68 and a beta of 0.41. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $199.99. The business has a 50 day moving average of $178.46 and a 200-day moving average of $164.46.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.49. The company had revenue of $216.28 million for the quarter, compared to the consensus estimate of $163.17 million. On average, analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Cantor Fitzgerald boosted their price target on shares of Ascendis Pharma A/S from $200.00 to $203.00 and gave the stock an "overweight" rating in a report on Friday, August 8th. Royal Bank Of Canada boosted their price target on shares of Ascendis Pharma A/S from $210.00 to $230.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Bank of America boosted their price target on shares of Ascendis Pharma A/S from $201.00 to $216.00 and gave the stock a "buy" rating in a report on Monday, June 9th. UBS Group reissued a "buy" rating and issued a $307.00 price target (up from $306.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Finally, Wedbush boosted their price target on shares of Ascendis Pharma A/S from $212.00 to $220.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Fifteen analysts have rated the stock with a Buy rating, According to MarketBeat, Ascendis Pharma A/S currently has an average rating of "Buy" and a consensus price target of $243.36.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.